WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Katie Gu
Associate
Corporate
Palo Alto
katie.gu@wsgr.com

D650-849-3057

Download vCard
Open PDF

Katie is a corporate associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she focuses on the digital health and life sciences industries.

During law school, Katie served as the editor-in-chief of the Harvard Journal of Law & Technology and was a student fellow at the Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics.

Previously, Katie worked as a project manager at Genentech.

Experience

Katie is a corporate associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she focuses on the digital health and life sciences industries.

During law school, Katie served as the editor-in-chief of the Harvard Journal of Law & Technology and was a student fellow at the Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics.

Previously, Katie worked as a project manager at Genentech.

Education
  • J.D., Harvard Law School

    Cum Laude

  • M.S., Bioengineering, Stanford University

    Digital Health Fellow, Stanford Byers Center for Biodesign

  • B.S. and B.A., Biology and English Literature, Stanford University

    Graduated with Distinction, Collegiate All-American

Admissions
  • State Bar of California
Credentials
Education
  • J.D., Harvard Law School

    Cum Laude

  • M.S., Bioengineering, Stanford University

    Digital Health Fellow, Stanford Byers Center for Biodesign

  • B.S. and B.A., Biology and English Literature, Stanford University

    Graduated with Distinction, Collegiate All-American

Admissions
  • State Bar of California
Focus Areas
  • Biotech
  • Corporate
  • Digital Health
  • Life Sciences
  • Medical Devices
Recent Insights
Client Highlights
Firm Advises ABL Bio on Strategic Alliance and Equity Investment with Eli Lilly
On November 14, 2025, ABL Bio announced a broad strategic research and development alliance with Eli Lilly and Company, establishing a multi-program collaboration to advance next-generation therapeutics using ABL Bio’s Grabody Platform. Wilson Sonsini Goodrich & Rosati advised ABL Bio on the license, research, and collaboration agreement, which is valued at up to $2.602 billion, including a $40 million upfront payment. Through this partnership, ABL Bio and Lilly will jointly explore and develop multiple therapeutic modalities across a range of disease areas, marking a significant expansion of ABL Bio’s platform-driven global collaborations.
Learn More
Client Highlights
Wilson Sonsini Advises Sage Care on $20 Million Funding as Company Emerges from Stealth
On October 17, 2025, Sage Care, a platform designed to eliminate healthcare navigation inefficiencies through a combination of clinically intelligent AI agents and advanced optimization algorithms, announced its public launch with $20 million in funding led by Yosemite and continued support from General Catalyst, Metrodora, OVTR.VC, SV Angel, Liquid 2, Seven Stars, Refract Ventures, AME Cloud Ventures, and Apolo Ohno. Wilson Sonsini Goodrich & Rosati advised Sage Care on the transaction.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.